Vimarsana
Biggest News Aggregation in the World

Page 2 - Par Pharm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Par Pharm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Par Pharm Today - Breaking & Trending Today

CVC Files Opposition to Senior Party Sigma-Aldrich's Substantive Preliminary Motion No. 1 to Change Count in Interference No. 106,132 | McDonnell Boehnen Hulbert & Berghoff LLP - Vimarsana News

CVC Files Opposition to Senior Party Sigma-Aldrich's Substantive Preliminary Motion No. 1 to Change Count in Interference No. 106,132 | McDonnell Boehnen Hulbert & Berghoff LLP

On November 19th, Senior Party Sigma-Aldrich filed its Substantive Preliminary Motion No. 1 in CRISPR Interference No. 106,132, asking the Board to substitute the Count pursuant to 37...

Navigating Trade Secret Identification During Discovery: Timing & Scope - Intellectual Property - Vimarsana News

Navigating Trade Secret Identification During Discovery: Timing & Scope - Intellectual Property

A trade secret derives its value by being kept secret, yet a trade secret owner is required to identify its trade secret at some point during litigation to apprise the defendant as to what information...

Source: mondaq.com
"About" Patent Claim Construction: Par v. Hospira | Harris Beach PLLC - Vimarsana News

"About" Patent Claim Construction: Par v. Hospira | Harris Beach PLLC

To embed, copy and paste the code into your website or blog: The use of the word “about” in a patent claim as part of a numeric range might permit the patent holder to preclude competitor formulations falling outside the approximate range, as illustrated in a fairly recent decision Par Pharm., Inc. v. Hospira, Inc., 835 F. App'x 578 (Fed. Cir. 2020). Par sued Hospira for patent infringement after Hospira filed an ANDA seeking to market a generic version of Par’s Adrenalin ® epinephrine injection. At issue was the scope of the patent claim listing the approximate amounts of tonicity, ...

Par Pharm., Inc. v. Hospira, Inc. | Robins Kaplan LLP - Vimarsana News

Par Pharm., Inc. v. Hospira, Inc. | Robins Kaplan LLP

Adrenalin® (epinephrine injection) Case Name: Par Pharm., Inc. v. Hospira, Inc., No. 2020-1273, 2020 WL 6846347 (Fed. Cir. Nov. 23, 2020) (Circuit Judges Dyk, Taranto, and Stoll presiding; Opinion by Taranto, J.) (Appeal from D. Del., Bataillon, J.) Drug Product and Patent(s)-in-Suit: Adrenalin® (epinephrine injection); U.S. Patents Nos. 9,119,876 (“the ’876 patent”) and 9,295,657 (“the ’657 patent”) Nature of Case and Issue(s) Presented: In 2017, Hospira filed an ANDA seeking permission to market a generic version of Par’s Adrenalin® epinephrine injection. Par sued Hospira ...